Alexandria, VA – May 26, 2026 – The American Association for the Study of Liver Diseases (AASLD) is pleased to announce two new multinational consensus statements, published today in HEPATOLOGY, the premier publication in the field of liver disease.
Developed through broad international collaboration, these statements provide critical guidance and help advance global alignment in hepatology research, diagnosis, and clinical care.
“As a global leader in hepatology, AASLD continues to convene international experts to advance rigorous, evidence-based science and address complex challenges in liver disease,” said Saul J. Karpen, MD, PhD, FAASLD, President of AASLD. “It was an honor to collaborate with our global sister societies on these important articles. Consensus-driven international guidance is essential to advancing liver health worldwide and translating emerging science into clearer, more unified standards for diagnosis, treatment, prevention, and future research.”
A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF
Noncirrhotic portal hypertension has historically been described using heterogeneous and region-specific terminology, such as idiopathic portal hypertension (IPH), noncirrhotic portal fibrosis (NCPF), obliterative portal venopathy, and nodular regenerative hyperplasia, leading to substantial variability in diagnosis, reporting, and international research collaboration.
Differences in guideline definitions from major societies, together with the presence of characteristic histologic lesions in patients without clinically overt portal hypertension, have further complicated disease classification.
To address these challenges, a large, multisociety, international initiative was convened to harmonize nomenclature and diagnostic criteria. Representatives from liver, pathology, and pediatric hepatology societies across the Americas, Europe, and Asia participated in a structured consensus process that included specialized working groups and external Delphi validation. The initiative produced a globally aligned and implementable diagnostic framework.
Consensus was reached that the terms porto-sinusoidal vascular disorder (PSVD) and NCPF may be used interchangeably when identical diagnostic criteria are applied, and that they should be written as PSVD or NCPF.
View the full consensus statement in HEPATOLOGY.
EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis
Drug development in primary biliary cholangitis (PBC) has led to the conditional approval of three second-line therapies, yet the transition to full regulatory approval remains challenging.
To address limitations, AASLD and European Association for the Study of the Liver (EASL) commissioned an international, multi-stakeholder consensus panel to conduct a modified Delphi process to review current evidence, identify unmet research needs, and create a framework aligned with regulatory expectations to guide ongoing and future research in PBC.
The Delphi process resulted in agreement on 16 statements and 42 recommendations across three thematic domains. Collectively, these consensus recommendations provide a comprehensive and pragmatic framework to support and expand the existing regulatory pathway for the development and approval of new therapies in PBC.
View the full consensus statement in HEPATOLOGY.
# # #
About AASLD
The American Association for the Study of Liver Diseases (AASLD), founded in 1950, is the leading global organization of scientists and health care professionals dedicated to advancing the science and practice of hepatology and improving liver health for all. Through cutting-edge research, professional education, practice guidance, advocacy, and collaboration, AASLD works to prevent, treat, and ultimately cure liver disease. The association supports a vibrant, multidisciplinary community committed to driving innovation and improving patient outcomes worldwide. Learn more at www.aasld.org.
About HEPATOLOGY
HEPATOLOGY publishes original, peer-reviewed articles on all aspects of liver structure, function, and disease. Each month, the journal highlights high-impact research spanning immunology, chronic hepatitis, viral hepatitis, cirrhosis, metabolic liver diseases, liver cancer, alcohol-associated liver disease, and drug metabolism.